Literature DB >> 6150235

Genetic markers in narcolepsy.

N Langdon, K I Welsh, M van Dam, R W Vaughan, D Parkes.   

Abstract

Narcolepsy has long been known to have a hereditary familial basis. All of 37 patients with narcolepsy expressed the major histocompatibility complex antigen HLA DR2 compared with 21.5% of 200 normal controls. This finding confirms the genetic basis for the disease, and furthermore links it with the short arm of chromosome 6. If the sleep disturbance in narcolepsy is due to a gene-determined defect in a neurotransmitter or receptor factor, the responsible agent may be DR2 itself or an enzyme determinant linked to DR2. This is the strongest HLA-disease association so far discovered.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6150235     DOI: 10.1016/s0140-6736(84)92742-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

1.  HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis.

Authors:  H Zetterquist; U Broomé; K Einarsson; O Olerup
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 2.  Genome-wide association studies of sleep disorders.

Authors:  David M Raizen; Mark N Wu
Journal:  Chest       Date:  2011-02       Impact factor: 9.410

Review 3.  Major histocompatibility complex class II genes and systemic sclerosis.

Authors:  D Briggs; K I Welsh
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

4.  Narcolepsy and the T-cell receptor.

Authors:  Timothy J Vyse
Journal:  Nat Genet       Date:  2009-06       Impact factor: 38.330

5.  The narcolepsy-associated DRw15,DQw6,Dw2 haplotype has no unique HLA-DQA or -DQB restriction fragments and does not extend to the HLA-DP subregion.

Authors:  O Olerup; M Schaffer; J Hillert; C Sachs
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

6.  Unusual HLA-DR/DQ haplotypes: two different breakpoints in two different DR2-DQw3 haplotypes.

Authors:  A Andreas; D Chandanayingyong; W Attatippaholkun; M Sirikong; R Klaythong; E Keller; E D Albert
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

7.  The science of clinical neurology.

Authors:  J Walton
Journal:  J R Soc Med       Date:  1986-01       Impact factor: 5.344

Review 8.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

9.  IgH (mu-switch and gamma-1) region restriction fragment length polymorphism in human narcolepsy.

Authors:  S M Singh; C F George; R N Ott; C Rattazzi; C Guilleminault; W C Dement; E Mignot
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

10.  Polymorphism located between CPT1B and CHKB, and HLA-DRB1*1501-DQB1*0602 haplotype confer susceptibility to CNS hypersomnias (essential hypersomnia).

Authors:  Taku Miyagawa; Makoto Honda; Minae Kawashima; Mihoko Shimada; Susumu Tanaka; Yutaka Honda; Katsushi Tokunaga
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.